Huntington's disease, formerly known as "St. Vitus' dance," is a rare and incurable brain disorder characterized by movement ...

After years of heartbreak, researchers have found an experimental treatment that can slow the progression of Huntington’s ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Ingrezza sprinkle capsules to treat adults with Huntington’s disease chorea or tardive ...

Researchers announce breakthrough results for AMT-130, the first disease-modifying treatment for Huntington's disease, with ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the open-label KINECT®-HD2 study demonstrating an established long-term safety profile, tolerability and sustained ...

Qure N.V. (QURE) on Wednesday said that a high dose of its experimental drug AMT-130 demonstrated a statistically significant slowing of disease progression in Huntington’s disease in an early-to-mid ...

The drug valbenazine statistically improves chorea, a movement disorder commonly associated with Huntington's disease, when compared to a placebo, according to a recent international study led by ...

A new drug was approved for Huntington's chorea in 2023, and novel insights about Huntington's disease emerged in new research. Valbenazine for Huntington's Chorea In August, the FDA expanded the ...

Neurocrine Biosciences is a pharmaceutical company specializing in the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company recently submitted a proposal for the use ...

The drug valbenazine statistically improves chorea, a movement disorder commonly associated with Huntington's disease, when compared to a placebo. The drug valbenazine statistically improves chorea, a ...

A drug currently approved for tardive dyskinesia (TD) is also effective at treating Huntington's disease (HD)–associated chorea, a movement disorder that affects most patients with HD, new phase 3 ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify [email protected] if there are concerns regarding accuracy of the transcription.